The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: An overview

British Journal of Dermatology, Supplement

Volumn 149, Issue 66, 2003, Pages 53-56

  Stockfleth, E ^a   Trefzer, U ^a   Garcia Bartels, C ^a   Wegner, T ^a   Schmook, T ^a   Sterry, W ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Basal cell carcinoma (BCC); Imiquimod 5 cream; Immune response modifier; Toll like 7 agonist

Indexed keywords

ALPHA INTERFERON; IMIQUIMOD; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA;

AGONIST; BASAL CELL CARCINOMA; CLINICAL TRIAL; CONFERENCE PAPER; CREAM; CYTOKINE PRODUCTION; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; ERYTHEMA; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN EDEMA;

EID: 0347951007     PISSN: 0366077X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0366-077x.2003.05626.x     Document Type: Conference Paper

References (17)

1. Lombardi T, Odell EW, Morgan PR. p53 immunohistochemistry of odontogenic keratocysts in relation to recurrence, basal-cell budding and basal-cell naevus syndrome. Arch Oral Biol 1995; 40: 1081-4.
2. Ogden GR, Chisholm DM, Kiddie RA, Lane DP. p53 protein in odontogenic cysts: increased expression in some odontogenic keratocysts. J Clin Pathol 1992; 45: 1007-10.
3. Farndon PA, Del Mastro RG, Evans DG, Kilpatrick MW. Location of gene for Gorlin syndrome. Lancet 1992; 339: 581-2.
4. Reis A, Kuster W, Linss G et al. Localisation of gene for the naevoid basal-cell carcinoma syndrome. Lancet 1992; 339: 617.
5. Johnson RL, Rothmann AL, Xie J et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272: 1668-71.
6. Hahn H, Wicking C, Zaphiropoulous PG et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996; 85: 841-51.
7. Miller RL, Gerster JF, Owens ML et al. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 1999; 21: 1-14.
8. Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MYD88-dependent signaling pathway. Nat Immunol 2002; 3: 196-200.
9. Stockfleth E, Meyer T, Benninghoff B et al A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002; 138: 1498-502.
10. Greenway HT, Cornell RC, Tanner DJ, Peets E, Bordin GM, Nagi C. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol 1986; 15: 437-43.
11. Hunt MJ, Halliday GM, Weedon D, Cooke BE, Barnetson RS. Regression In basal cell carcinoma: an immunohistological analysis. Br J Dermatol 1994; 130: 1-8.
12. Beutner KR, Geisse JR, Helman D et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41: 1002-7.
13. Marks R, Gebauer K, Shumack S et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multi center 6-week dose response trial. J Am Acad Dermatol 2001; 44: 807-13.
14. Geisse JK, Rich P, Pandya A et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47: 390-8.
15. Sterry W, Ruzicka T, Herrera E et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomised studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002; 147: 1227-36.
16. Shumack S, Robinson J, Kossard S et al. Amies M, Owens M. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Arch Dermatol 2002; 138: 1165-71.
17. Stockfleth E, Ulrich C, Hauschild A et al. Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. Eur J Dermatol 2002; 12: 569-72.